JP7445657B2 - オルニチントランスカルバミラーゼ欠損症を処置するための組成物および方法 - Google Patents

オルニチントランスカルバミラーゼ欠損症を処置するための組成物および方法 Download PDF

Info

Publication number
JP7445657B2
JP7445657B2 JP2021531945A JP2021531945A JP7445657B2 JP 7445657 B2 JP7445657 B2 JP 7445657B2 JP 2021531945 A JP2021531945 A JP 2021531945A JP 2021531945 A JP2021531945 A JP 2021531945A JP 7445657 B2 JP7445657 B2 JP 7445657B2
Authority
JP
Japan
Prior art keywords
seq
mrna
otc
sequence
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021531945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513718A5 (enExample
JP2022513718A (ja
Inventor
ジー ペレス－ガルシア，カルロス
清 立川
大輝 松田
チブクラ，パドマナブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arcturus Therapeutics Inc
Original Assignee
Arcturus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcturus Therapeutics Inc filed Critical Arcturus Therapeutics Inc
Publication of JP2022513718A publication Critical patent/JP2022513718A/ja
Publication of JP2022513718A5 publication Critical patent/JP2022513718A5/ja
Application granted granted Critical
Publication of JP7445657B2 publication Critical patent/JP7445657B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1018—Carboxy- and carbamoyl transferases (2.1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/03—Carboxy- and carbamoyltransferases (2.1.3)
    • C12Y201/03003—Ornithine carbamoyltransferase (2.1.3.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021531945A 2018-12-06 2019-12-05 オルニチントランスカルバミラーゼ欠損症を処置するための組成物および方法 Active JP7445657B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776302P 2018-12-06 2018-12-06
US62/776,302 2018-12-06
PCT/US2019/064786 WO2020118115A1 (en) 2018-12-06 2019-12-05 Compositions and methods for treating ornithine transcarbamylase deficiency

Publications (3)

Publication Number Publication Date
JP2022513718A JP2022513718A (ja) 2022-02-09
JP2022513718A5 JP2022513718A5 (enExample) 2022-12-12
JP7445657B2 true JP7445657B2 (ja) 2024-03-07

Family

ID=70972469

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531945A Active JP7445657B2 (ja) 2018-12-06 2019-12-05 オルニチントランスカルバミラーゼ欠損症を処置するための組成物および方法

Country Status (9)

Country Link
US (3) US11685906B2 (enExample)
EP (2) EP4299750A3 (enExample)
JP (1) JP7445657B2 (enExample)
AU (2) AU2019394996B2 (enExample)
CA (1) CA3122080A1 (enExample)
ES (1) ES2960692T3 (enExample)
HU (1) HUE064076T2 (enExample)
PL (1) PL3891274T3 (enExample)
WO (1) WO2020118115A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022520148A (ja) * 2018-12-06 2022-03-29 アークトゥラス・セラピューティクス・インコーポレイテッド 修飾タンパク質および関連の処置方法
PL3891274T3 (pl) 2018-12-06 2024-03-25 Arcturus Therapeutics, Inc. Kompozycje i sposoby leczenia niedoboru transkarbamylazy ornityny
WO2021178510A1 (en) * 2020-03-03 2021-09-10 Arcturus Therapeutics, Inc. Compositions and methods for the treatment of ornithine transcarbamylase deficiency
WO2022204370A1 (en) * 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
WO2022235838A1 (en) 2021-05-07 2022-11-10 Helix Nanotechnologies, Inc. Modified ribonucleic acids and uses thereof
WO2023028469A2 (en) * 2021-08-23 2023-03-02 The Board Of Trustees Of The Leland Stanford Junior University Targeted integration at beta-globin locus in human hematopoietic stem and progenitor cells

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014170896A2 (en) 2013-04-15 2014-10-23 Bio Blast Pharma Ltd. Mitochondrial proteins constructs and uses thereof
WO2015017519A1 (en) 2013-07-30 2015-02-05 Phaserx, Inc. Block copolymers and their conjugates or complexes with oligonucleotides
WO2015138348A1 (en) 2014-03-09 2015-09-17 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
WO2016118697A1 (en) 2015-01-21 2016-07-28 Phaserx, Inc. Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
WO2017218524A1 (en) 2016-06-13 2017-12-21 Rana Therapeutics, Inc. Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
WO2018127382A1 (en) 2017-01-03 2018-07-12 Ethris Gmbh Ornithine transcarbamylase coding polyribonucleotides and formulations thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007065A1 (en) 1990-10-12 1992-04-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Modified ribozymes
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
EP1903054A3 (de) 2001-06-05 2008-07-23 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie
CA2530248A1 (en) 2003-06-25 2005-01-06 Gencia Corporation Modified vectors for organelle transfection
WO2005056752A2 (en) 2003-10-24 2005-06-23 Gencia Corporation Methods and compositions for delivering polynucleotides
HUE043492T2 (hu) 2005-08-23 2019-08-28 Univ Pennsylvania Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására
WO2008016473A2 (en) 2006-07-28 2008-02-07 Applera Corporation Dinucleotide mrna cap analogs
WO2009058911A2 (en) 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
JP5697988B2 (ja) 2007-12-27 2015-04-08 プロチバ バイオセラピューティクス インコーポレイティッド 干渉ｒｎａを使用したポロ様キナーゼ発現のサイレンシング方法
JP5749494B2 (ja) 2008-01-02 2015-07-15 テクミラ ファーマシューティカルズ コーポレイション 核酸の送達のための改善された組成物および方法
NZ588583A (en) 2008-04-15 2012-08-31 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
JP5777519B2 (ja) 2008-10-09 2015-09-09 テクミラ ファーマシューティカルズ コーポレイション 改良されたアミノ脂質および核酸の送達方法
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
EP4241767B1 (en) 2008-11-10 2024-10-23 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
US20120101148A1 (en) 2009-01-29 2012-04-26 Alnylam Pharmaceuticals, Inc. lipid formulation
SG176553A1 (en) 2009-05-05 2012-01-30 Muthiah Manoharan Lipid compositions
TR201811076T4 (tr) 2009-06-10 2018-08-27 Arbutus Biopharma Corp Geliştirilmiş lipit formulasyonu.
KR101161622B1 (ko) * 2009-08-31 2012-07-04 헬릭스 주식회사 번역 효율 증진용 ｄｎａ 단편 및 이를 포함하는 재조합 벡터
PL3338765T3 (pl) 2009-12-01 2019-06-28 Translate Bio, Inc. Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych
CA2800401C (en) 2010-06-03 2020-09-15 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
PT2717893T (pt) 2011-06-08 2019-08-20 Translate Bio Inc Composições de nanopartículas lipídicas e métodos para transferência de arnm
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
EP4721752A2 (en) 2011-12-30 2026-04-08 Cellscript, Llc Herstellung und verwendung von in vitro-synthetisierter ssrna zur einführung in säugetierzellen zur induktion einer biologischen oder biochemischen wirkung
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US20140090108A1 (en) 2012-09-18 2014-03-27 Freydoun Garabagi Vectors and Methods For Enhancing Recombinant Protein Expression in Plants
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
CA2901969A1 (en) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of forbes-cori disease
US20160022840A1 (en) 2013-03-09 2016-01-28 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
WO2015051169A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
MX2016005239A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Tratamiento con acido ribonucleico mensajero para la fenilcetonuria.
NZ720174A (en) 2013-11-18 2018-11-30 Arcturus Therapeutics Inc Ionizable cationic lipid for rna delivery
WO2015192092A1 (en) 2014-06-13 2015-12-17 Valerion Therapeutics, Llc Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders
AU2015338923B2 (en) 2014-11-02 2021-10-21 Arcturus Therapeutics, Inc. Messenger UNA molecules and uses thereof
EP3218508A4 (en) 2014-11-10 2018-04-18 Modernatx, Inc. Multiparametric nucleic acid optimization
WO2016077125A1 (en) 2014-11-10 2016-05-19 Moderna Therapeutics, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
HK1244479A1 (zh) 2014-11-18 2018-08-10 阿克丘勒斯治疗公司 用於rna递送的可电离阳离子脂质
US9709490B2 (en) 2014-12-08 2017-07-18 Canon Kabushiki Kaisha Refractive index distribution measuring method, refractive index distribution measuring apparatus, and optical element manufacturing method
CN108136040B (zh) 2015-07-31 2022-03-01 阿克丘勒斯治疗公司 用于药物递送的多配体试剂
HUE064227T2 (hu) 2015-09-21 2024-02-28 Trilink Biotechnologies Llc Módszer 5'-sapkával ellátott rns-ek szintetizálására
WO2017100551A1 (en) 2015-12-09 2017-06-15 Alexion Pharmaceuticals, Inc. HETEROLOGOUS UTR SEQUENCES FOR ENHANCED mRNA EXPRESSION
US9834510B2 (en) 2015-12-30 2017-12-05 Arcturus Therapeutics, Inc. Aromatic ionizable cationic lipid
IL308824A (en) 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
WO2018075827A1 (en) 2016-10-19 2018-04-26 Arcturus Therapeutics, Inc. Trinucleotide mrna cap analogs
MX2019004913A (es) 2016-10-26 2019-09-16 Curevac Ag Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
JP7560946B2 (ja) 2016-11-10 2024-10-03 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの皮下送達
WO2018119163A1 (en) 2016-12-21 2018-06-28 Payne Joseph E Ionizable cationic lipid for rna delivery
US10526284B2 (en) 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US10383952B2 (en) 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US10227302B2 (en) 2017-02-09 2019-03-12 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US11407800B2 (en) 2017-02-28 2022-08-09 Arcturus Therapeutics, Inc. Translatable molecules and synthesis thereof
US11377643B2 (en) 2017-05-31 2022-07-05 Ultragenyx Pharmaceutical Inc. Therapeutics for glycogen storage disease type III
WO2018222890A1 (en) 2017-05-31 2018-12-06 Arcturus Therapeutics, Inc. Synthesis and structure of high potency rna therapeutics
EP3714048B1 (en) 2017-11-22 2025-04-09 ModernaTX, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
US11167043B2 (en) 2017-12-20 2021-11-09 Translate Bio, Inc. Composition and methods for treatment of ornithine transcarbamylase deficiency
PL3891274T3 (pl) 2018-12-06 2024-03-25 Arcturus Therapeutics, Inc. Kompozycje i sposoby leczenia niedoboru transkarbamylazy ornityny
CA3133858A1 (en) 2019-03-19 2020-09-24 Arcturus Therapeutics, Inc. Method of making lipid-encapsulated rna nanoparticles
WO2021178510A1 (en) 2020-03-03 2021-09-10 Arcturus Therapeutics, Inc. Compositions and methods for the treatment of ornithine transcarbamylase deficiency

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014170896A2 (en) 2013-04-15 2014-10-23 Bio Blast Pharma Ltd. Mitochondrial proteins constructs and uses thereof
WO2015017519A1 (en) 2013-07-30 2015-02-05 Phaserx, Inc. Block copolymers and their conjugates or complexes with oligonucleotides
WO2015138348A1 (en) 2014-03-09 2015-09-17 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
WO2016118697A1 (en) 2015-01-21 2016-07-28 Phaserx, Inc. Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
WO2017218524A1 (en) 2016-06-13 2017-12-21 Rana Therapeutics, Inc. Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
WO2018127382A1 (en) 2017-01-03 2018-07-12 Ethris Gmbh Ornithine transcarbamylase coding polyribonucleotides and formulations thereof

Also Published As

Publication number Publication date
ES2960692T3 (es) 2024-03-06
US12398379B2 (en) 2025-08-26
US20200181584A1 (en) 2020-06-11
PL3891274T3 (pl) 2024-03-25
EP3891274A4 (en) 2022-08-31
EP4299750A2 (en) 2024-01-03
CA3122080A1 (en) 2020-06-11
AU2026200747A1 (en) 2026-02-26
EP3891274A1 (en) 2021-10-13
AU2019394996B2 (en) 2025-11-06
JP2022513718A (ja) 2022-02-09
US20240002815A1 (en) 2024-01-04
US11685906B2 (en) 2023-06-27
AU2019394996A1 (en) 2021-07-29
EP3891274B1 (en) 2023-10-18
WO2020118115A1 (en) 2020-06-11
US20260078356A1 (en) 2026-03-19
HUE064076T2 (hu) 2024-02-28
EP4299750A3 (en) 2024-07-10
EP3891274C0 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
US12398379B2 (en) Compositions and methods for treating ornithine transcarbamylase deficiency
US20220340886A1 (en) Therapeutics for glycogen storage disease type iii
US12351834B2 (en) Compositions and methods for the treatment of ornithine transcarbamylase deficiency
JP2023524071A (ja) 嚢胞性線維症を治療するための核酸及び方法
WO2020097493A1 (en) Negatively charged peg-lipid conjugates
IL310107A (en) RNA vaccines
US11939600B2 (en) Compositions and methods for treating phenylketonuria
US20220220189A1 (en) Compositions and methods for treatment of hemochromatosis
WO2025024442A1 (en) Compositions and methods for treating conditions associated with bsep deficiency

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20210803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240123

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240226

R150 Certificate of patent or registration of utility model

Ref document number: 7445657

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150